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Abstract 
The detection Iimit of the lacl transgenic mouse mutagenicity assay lies, in practice, at approximately a 50-100% 
increase in mutant frequency in treated animals over controls. The sensitivity of this assay in detecting genotoxins 
can be markedly improved by subchronic rather than acute application of the test compound. The lac/ transgenic 
mouse mutagenicity assay was compared quantitatively to rodent carcinogenicity tests and to presently used in vivo 
mutagenicity assays. With the genotoxic carcinogens tested thus far, a rough correlation between mutagenic potency 
and carcinogenic potency was observed: on average, to obtain a doubling in lacl mutant frequency the mice bad to 
be treated with a total dose equal to 50 times the TD50 daily dose Ievel. This total dose could be administered eilher 
at a high dose rate within a few days or, preferably, at a low dose rate over several weeks. This analysis also 
indicated that a lacl experiment using a 250-day exposure period would give a detection Iimit approximately equal to 
that of a long-term carcinogenicity study. In comparison to the micronucleus test or the chromosome aberration 
assay, acute sturlies with the presently available lacl system offered no increase in sensitivity. However, subchronic 
lacl sturlies (3-4-month exposure) resulted in an increase in sensitivity over the established tests by 1-2 orders of 
magnitude (shown with 2-acetylaminofluorene, N-nitrosomethylamine, N-nitrosomethylurea and urethane). 1t is 
concluded that a positive result in the lacl test can be highly predictive of carcinogenicity butthat a negative result 
does not provide a large margin of safety. 
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1. Introduction 
The advent of transgenic technology has 
opened up exciting new possibilities for muta-
genicity testing in mammals. Using the bacterial 
lacl gene as a reporter gene, transgenic mice 
have been constructed that could allow genotoxic 
agents to be examined in vivo in practically any 
desired target organ (Kahler et al., 1990). A de-
scription of the assay is given in Fig. 1. 
Questions surrounding the assay at present 
include (1) what dose Ievels are necessary to 
induce measurable effects, (2) in what range do 
the spontaneaus and induced mutant frequencies 
Iie, (3) what factors influence the detection Iimit 
of the test, and (4) how do the sensitivity and 
specificity of the assay compare with the other in 
vivo systems for detecting mutagenicity or car-
cinogenici ty? 
1. 
2. isolate DNA 
in vitro 
3. 
packaging 
In this review, results of lacl studies from the 
Iiterature (Kohler et al., 1991a,b) and from our 
own studies ( Gunz et al., 1993; Shephard et al., 
1993; unpublished data) have been compiled and 
compared to results on the same compounds in 
long-term rodent bioassays. the micronucleus and 
chromosome aberration tests (metaphase analy~ 
sis) in vivo. The emphasis is on a quantitative 
comparison of the sensitivities of the test systems. 
In addition, factors which affect the Iimit of de~ 
tection of the lacl assay are examined, both those 
which can be influenced by experin1ental design 
and those inherent in the system. 
2. Methods 
2.1. Lac/ mutagenicity assay data 
Experiments involving both acute (1 or 5 days) 
and subchronic (1, 3 or 4 months) exposure to 
test chemieals were included in this analysis. For 
each compound and exposure period tested, the 
lowest dose leading to a significant increase in 
Fig. 1. Principle of the lacl mouse mutagenicity assay. ( 1) The 
genome of the mice contains multiple copies of a Iambda 
vector (bars) bearing the lacl gene (striped), stably inserted 
into an autosomal chromosome. lf the mice are exposed to 
genotoxins, there is a small probability that a mutation wi11 
occur somewhere along the inserted sequence (symbolised by 
an x ). (2) Genomic DNA is purified from organs of interest. 
(3) The Iambda vector bearing the target gene is excised from 
the genomic DNA and packaged in vitro into infective Iambda 
bacteriophage particles. This step is accomplished by mixing 
the genomic DNA with a commercially available packaging 
extract that contains all the enzymes and the virus coat 
proteins necessary to excise the vector and build the phage 
particles. (4) The particles are allowed to infect an excess of 
E. coli bacteria. On agar plates, plaques from infected bacte-
ria show up as holes against a lawn of uninfected bacteria. 
Mutations in the marker lacl gene are detected using a simple 
colour test: the lacl gene encodes a protein that represses 
expression of JacZ, a bacterial gene which codes for the 
enzyme ß-galactosidase (ß-ga]). lf the lac/ repressor is inacti-
vated hy a mutation, lacZ will be transcribed in the host 
bacteria and ß-gal activity expressed. ß-Gal activity is de-
tected with the chromogenic substrate X-Gal, which makes a 
hlue product upon cleavage. On the agar plates one thus finds 
isolated blue plaques containing the mutated target gene 
amongst a vast majority of colourless plaques bearing the 
intact repressor. 
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mutant frequency was compiled. Where data from 
more than one organ or more than one expres-
sion period (period between dosing with carcino-
gen and killing the animal) were available, the 
highest observed mutant frequency is reported 
here. The expression period in the acute studies 
was typically 1-12 days; no additional expression 
period following dosing was used in the chronic 
studies. Note that in some cases only one dose 
Ievel was tested. 
2.2. Micronucleus test and chromosome aberration 
data 
A description of the two mutagenicity tests is 
provided in two reviews (Preston et al., 1981; 
Heddle et al., 1983). Data on all the compounds 
that have also been tested in /acl mice were 
compiled from the original Iiterature; the specific 
references consulted are noted in Table 3. The 
Iowest dose Ieading to a significant increase in 
micronuclei or chromosome aberrations (LED, 
lowest effective dose) was recorded. Where data 
from more than one study were available, the 
Table 2 
geometric mean of the LEDs was calculated. 
Mouse data were used wherever possiblc; if lac.k-
ing, rat data were taken as substitute. In some 
cases only one dose Ievel was mentioned in the 
publications. 
2.3. Carcinogenic potency estinzates 
An estimate of the carcinogenic strength of the 
compounds was found in the carcinogenicity po-
tency data base of Gold et al. (1991). In this data 
base, the results of long-term rodent bioassays 
have been summarised, and a measure of the 
potency of each compound is given as the TD50 . 
The TD50 is defined as the daily dose of a chemi-
cal (per kg body weight per day) that results in a 
50% decrease in the nurober of tumour-free ani-
mals after lifetime exposure (2 years in rats and 
mice). The appropriate TD50 value was selected 
from the data base according to t he following 
hierarchy of criteria: (1) increase in tumour inci-
dence statistically significant ( P < 0.05); (2) mause 
as test species; (3) same sex as in mutagenicity 
study; (4) malignant tumours rather than benign; 
Variation in /ac/ mutant frequency in the liver amongst animals of the same treatment group (data from Gunz et al., 1993) 
Treatment Plaques Mutant Mutant frequency Mean mutant 
counted plaques ± Poissonian error frequency ± SD 
< x w-· 5> (xw-s> 
Control group I 212050 13 tU± 1.7 
163 880 14 8.5 ± 2.3 
191370 19 9.9 ± 2.3 
165 080 9 5.5 ± l.H 
7.5 ± 2.1 
Control group 2 193600 1l 5.7 ± 1.7 
170265 20 12 ± 3 
177200 24 14 ± 3 
10 ± 4 
2-AAF 75 ppm 148500 53 36 ± 5 
82195 lH 22 ± 5 
153600 37 24 ± 4 
27 ± 8 
2-AAF 150 ppm 157350 82 52 ± 6 
92650 28 30 ± 6 
73200 49 67 ±10 
51 ± 20 
Each Jine represents one animal. The Poissonian error of each mutant frequency estimate is given for each individual animal ( ± 1 
SD); the biological variability in each treatment group is expressed as the standard deviation around the mean. 
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(5) TD50 value for same organ as examined in 
mutagenicity study; (6) 2-year rather than a 
shorter exposure period. If the available data did 
not meet all the criteria, the data used to calcu-
late the TD50 were selected by waiving first the 
sixth criterion, next the fifth, and so on until the 
first satisfactory data set was found. 
2. 4. Calculations and statistics 
The "doubling dose" (DD) was defined as the 
total dose of carcinogen (daily dose integrated 
over treatment period) that would induce a mu-
tant frequency double that of control animals, 
assuming a linear dose response in the net mu-
tant frequency. The doubling dosewas calculated 
from the lacl mutant frequencies in Table 1 
according to the following formula: DD =(total 
dose of carcinogen)j[(induced - spontaneous 
mutant frequency) j(spontaneous mutant fre-
quency)). 
The confidence intervals for the mutant fre-
quencies given in Table 2 were calculated assum-
ing a Poisson distribution (Werner, 1984): 
k I ( n X F[oo,2k]) 5, p 5, [ ( k + 1) X F[2(k + l),oo)] jn 
where p = real mutant frequency, k = number of 
Table 3 
mutants, n = total number of plaque forming units 
(pfu) counted, Fn,fl = uncertainty factors from 2-
sided F-distribution table for a = 0.05. 
3. Results and discussion 
A summary of lacl experiments and results 
published thus far is given in Table 1, columns 
1-4. Spontaneous mutant frequencies vary some· 
what between Iabs, lying in the range of 2-8 X 
10-5 (column 3). At the doses chosen in these 
studies, induced mutant frequencies generally lay 
approximately 2-10-fold above the spontaneous 
values. 
3.1. Accumulation ofmutations in subchronic stud-
ies 
It is apparent that in the acute studies 0-5 
days) massive doses of carcinogen were necessary 
to produce a measurable effect; doses adminis-
tered are often in the range of overt toxicity. 
Considerably smaller doses gave significant ef-
fects in the subchronic studies (28-120 days), due 
to an accumulation of mutations over the expo· 
sure period. In the liver, an increase in sensitivity 
of the test was possible over quite a long time 
Comparison of the lowest reported daily doses of genotoxins (in mgjkg bw) that give statistically significant results in the lacl 
system vs. two standard in vivo mutagenicity tests (mouse data unless stated othetwise) 
Substance Lac/ assay a Micronucleus test Chromosome aberrations 
(No. of days, organ) (Reference) (Reference) 
Acute lac/ data 
Benzo[ a ]pyrene soo (1, spl) 44 (Heddle et al., 1983) 14S (rat; NIOSH, 1987) 
100 (5, spl) 
Cyclophosphamide 100 (1, spl) 38 (IARC, 1987) 13 ("animal"; IARC, 1987) 
N-Nitrosoethylurea 125 (1, spl) 140 (rat; Tates et al., 1986) 100 (Soukup and Au, 1975) 
50 (S, spl) 
N-Nitrosomethylurea 100 (5, spl) no data 8 (Frei and Venitt, 1975) 
Subchronic lacl data 
2-Acetylaminofluorene 80 (28, liv) 270 (Friedman and Staub, 1977; 30 (rat, 21 day exp.; 
11 (120, liv) Heddle et al., 1983) Hitachi et al., 1975) 
N-Nitrosodimethylamine 0.3 (lOS, liv) 44 (Friedman and Staub, 1977; 23 (rat; IARC, 1978; 
Watanabe et al., 1982; NIOSH, 1987) 
Heddle et al., 1983) 
N-Nitrosomethylurea 2.3 (lOS, liv) no data 8 (Frei and Venitt, 1975) 
Urethane 130 (lOS, tun) 220 (Heddle et al., 1983) 5000 (Colnaghi et al., 1969) 
a Iiv, liver; lun, Jung; spl, spleen. 
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period: after a 28-day exposure to 2-AAF, a dose 
of 80 mgl kgl day was required to produce a 
3-fold increase in mutant frequency, whereas af-
ter 120 days' exposure, 11 mgl kgl day sufficed to 
produce a 3.5-fold increase. The induced mutant 
frequency was roughly proportional to the inte-
gral of dose over time, i.e., the effect depended 
primarily on the total dose administered, inde-
pendent of the dosing schedule. A similar addi-
tive effect of repeated mutagen treatments has 
been observed with the compounds N-
nitrosoethylurea, methyl methanesulfonate and 
1,2-dimethylhydrazine in experiments using the 
D/b-1 locus as marker (Tao and Heddle, 1994 ). 
That subehrenie dosing allows the effects of 
small doses of mutagens to be detected could be 
important for the toxicological interpretation of 
the results. At high doses, overt toxicity can in-
duce regenerative hyperplasia and reduce the 
time available for repair enzymes to remove DNA 
darnage before it becomes fixed as mutations. 
Similarly, DNA repair capacities can be saturated 
or exhausted by high doses. The linear relation-
ships seen above do not hold true under these 
circumstances (Russell et al., 1982). Results of 
such experiments are more difficult to use for 
extrapolation down to low-dose human exposure 
Ievels. 
3. 2. Correlation between /ac/ results and carcino-
genic potency 
The TD50 was used as a standard measure of 
potency of carcinogens (Table 1, column 6); for 
the lac/ data, a DD was defined as a measure of 
potency (column 5). The definitions of both units 
are given in the Methods section. The DDs are 
compared to TD50 values in column 7. The corre-
lation between mutagenic potency and carcino-
genic potency is rather poor for the acute lacl 
data, the ratios DD I TD50 vary over a wide range, 
from 2.3 to 1300. With the subchronic lac/ data 
the DD 1 TD50 ratios are much more uniform and 
Iie between 13 and 100, i.e., within one order of 
magnitude of each other. The geometric mean of 
the ratios is 47. 
The selection of test substances and routes of 
administration can partly explain this difference 
in the correlations: mouse carcinogenicity data 
were available for most of the compounds se-
lected for chronic lacl studies, whereas only rat 
or primate carcinogenicity data were available for 
some of the compounds tested in the acute lacl 
studies. In acute studies the animals were usually 
dosed i.p., whereas in the carcinogenicity and 
subchronic lacl studies the substances were ad-
ministered in the feed or drinking water. A tighter 
correlation would be expected for the acute data 
if these factors matched. 
Certain other important factors related to the 
experimental protocol, the doses used and the 
argans examined in the acute and subehrenie lacl 
sturlies could also bear upon the correlation to 
carcinogenic potency: the selection of an appro-
priate expression period becomes less critical if 
dosing is chronic, and factors such as cytotoxicity 
that can indirectly influence the mutant fre-
quency are also Iess important at the Iower doses 
used in the Iong-term treatment (cf. previous 
section). Furthermore, examining mutants in the 
target organs would be expected to give a better 
correlation to carcinogenicity than using the 
spieen as a "marker organ". 
The rough correlation derived here between 
carcinogenic potency and mutagenicity in the lacl 
system predicts that a daily dose of genotoxin 
which produces a 50% tumour incidence after 2 
years should produce an approximately 100% in-
crease in lacl mutant frequency after about a 
50-day exposure period. This information could 
be useful in setting dose Ievels for future lacl 
studies. With the knowledge that, roughly speak-
ing, a total dose of 50 X TD50 will result in a 
doubling of the mutant frequency, the experimen-
tal design can include the appropriate dose groups 
and exposure periods to produce statistically sig-
nificant results. This correlation will also be used 
below in the comparison of the limits of detection 
of lacl and carcinogenicity tests. 
3.3. Limit of detection of a mutagenic effect in the 
lacl test 
The detection limit of the lac/ test is influ-
enced by several independent factors: (i) the 
background mutant frequency, (ii) the number of 
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plaques examined per animal, (iii) the animal-to-
animal variation in response to the mutagen, and 
(iv) the number of animals per group. Factors (ii) 
and (iv), in turn, are limited by reagent and 
labour costs. 
Since the frequency of mutants is extremely 
small, the data from each animal are expected to 
follow a Poisson distribution (Spiegel, 1990; to 
date, no significant deviation from a Poisson dis-
tribution has been reported for data from individ-
ual animals (W. Piegorsch, personal communica-
tion, 1993)). As a consequence, the standard devi-
ation (SD) of a mutant count is approximated by 
its square root. It therefore requires less effort to 
reach significance for a doubling of the mutant 
frequency (100% increase) in a tissue with a high 
background (BG) mutation rate than in one with 
a low natural rate. In a hypothetical case, based 
on a Poisson distribution of the data and disre-
garding animal-to-animal variation, a doubling of 
mutant frequency is significant at 95% confidence 
once 14 mutants (SD = ±3.7) have been regis-
tered in the control sample and 28 (SD = ± 5.3) 
in the treated sample, independent of whether 
the 14 are found amongst 200 000 or 700 000 
wild-type sequences (BG = 7 x lo-s or 2 X lo-s, 
respectively). For a detection Iimit of 50% in-
crease, the Poisson distribution requires that 42 
and 63 mutants be accumulated in control and 
treated samples, respectively (requires examina-
tion of 600000 when BG = 7 X 10-5 or 2.1 mil-
lion plaques at a background of 2 x 10-5). From 
a purely mathematical standpoint, the Iimit of 
detection that can be achieved depends primarily 
upon the effort one is willing to put into analysing 
plaques. 
The other main source of variability is the 
biological variation in response between individ-
ual anirnals of the sarne treatrnent group; this 
follows anormal distribution. Within one experi-
mental group, variations by a factor of 2 are not 
unusual (Table 2). The effect of this variation can 
be mitigated by (i) increasing the number of ani-
mals per group and (ii) counting enough plaques 
per animal to provide a reasonably precise esti-
mate of individual mutant frequencies. Table 2 
illustrates the relative importance of these two 
sources of error (Poissonian or "counting" error 
vs. standard deviation around the mean of one 
treatment group) in typical data from a lacl ex-
periment in our Iab. At these numbers of plaques 
(70 000-200 000 analysed per sample), both 
sources of variation contribute approximately 
equally to the error in the control groups, whereas 
the biological variability dominates in the treated 
groups. A comprehensive statistical analysis of all 
aspects of the test, both biological and technical, 
that can contribute to variability in the data is 
currently in progress in other research groups. 
Limitations on the number of plaques counted 
are primarily given by the not inconsiderable costs 
of reagents, materials and labour. As the lac/ test 
is currently conducted in our Iab, one person can 
prepare, package and analyse about 106 plaques 
per work week. Depending on the packaging effi-
ciency of the tissue being examined (in our hands: 
Jung, glandular stomach > kidney > forestomach, 
liver > bladder) and the quality of the particular 
DNA sample, it presently costs US$700-2500 in 
reagents and materials to produce 106 plaques 
(not including the animals themselves). However, 
it is likely that the testwill become more econom-
ical in the future once selectable systems and 
innovations to increase packaging yield and recy-
cle materials are introduced. 
We have developed a pragmatic strategy to 
optimise the use of resources. (1) More plaques 
are counted from control than from treated ani-
mals. (2) After each round of packaging we calcu-
late the confidence interval for each mutant fre-
quency, where the present Iimit of detection lies, 
and analyse with statistical methods whether an 
effect has reached statistical significance. We stop 
packaging a particular sample once (i) an effect is 
detectable at the desired Ievel of statistical signif-
icance, or (ii) the desired Iimit of detection has 
been reached. Given all the above variables, our 
practical Iimit of detection at the moment lies 
between a 50 and 100% increase in mutant fre-
quency. 
3.4. Sensitivity of /acl test vs. established muta-
genicity tests 
The lacl system was compared quantitatively 
to two of the most frequently used in vivo assays 
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for cytogenetic damage: the micronucleus test 
and the chromosome aberration assay. For each 
compound that has been examined with /acl mice., 
the lowest dose leading to a significant result in 
each test system has been compiled (Table 3). In 
some cases only one dose was recorded in the 
originalliterature, in these cases the true Iimit of 
detection is probably somewhat lower. 
Evident from the table is that in acute studies, 
lacl offers no sensitivity advantage over the estab-
lished assays. The doses of mutagen necessary to 
give a positive result in each of the test systems 
were qtiite similar. This result was somewhat 
unexpected, as this particular group of test chem-
ieals would be expected to preferentially cause 
gene mutations rather than chromosome aberra-
tions, and considering that the chromosome aber-
ration and micronucleus tests detect darnage in a 
marker tissue rather than in the target organ. 
However, the explanation lies at least partly in 
the different background mutation Ievels in the 
two types of test: note that the unit of analysis in 
the /ac/ test is the gene, whereas the cell is the 
unit of analysis for the micronucleus and chromo-
some aberration assays. 1f the background fre-
quency of gene mutations observed in the lac/ 
test is extrapolated and expressed as number of 
events per cell, one arrives at approximately: 
(5 X 10-5 mutations per gene) x (105 genes per 
cell) =· 5 mutation events per cell. 
Our detection Iimit would thus correspond to 
7.5-10 mutation events per cell. In contrast, the 
background rate of, e.g., micronucleus formation 
is :::::: 2 events/1000 cells; the Iimit of detection is 
a doubling or tripling of mutant frequency to 4-6 
events/1000 cells (Heddle et al., 1983). Back-
ground rates and detection Iimits in chromosome 
aberration assays are similar or slightly higher 
(Preston et al., 1981). The lower background rates 
of the micronucleus and chromosome aberration 
assays allowed these tests to detect smaller abso-
lute numbers of mutation events per cell (about 3 
orders of magnitude less). 
In cantrast to the above, in chronic studies the 
lacl test does offer an increase in sensitivity 1-2 
orders of magnitude above the Standard chromo-
some aberration and micronucleus tests, at least 
for these types of mutagen. For example, N-
nitrosodimethylamine produced detectable geno-
toxicity in the /acl test at a daily dose of only 0.3 
mgjkg over 105 days, whereas doses of 44 mgjkg 
and 23 mgjkg were necessary to produce a 
"positive" in the standard micronucleus and 
chromosome aberration assays (Table 3). It is to 
be hoped that the sensitivity advantage offered by 
Ionger exposure times will be exploited in the 
future. 
3.5. Limit of detection of the lac/ test vs. long-term 
rodent carcinogenicity studies 
In rodent carcinogenicity studies, the detection 
Iimit depends on the size of the study (number of 
animals used) and the spontaneaus tumour inci-
dence: for example, in a study with 40 control and 
40 treated animals and a spontaneous tumour 
incidence of 1%, the detection Iimit (95% confi-
dence Iimit) would lie at a 10% increase in tu-
mours (i.e., = TD 10 ; Caims, 1979). We will as-
sume here that this tumour incidence is induced 
at a dose rate of one-fifth of the TD50. 
The detection Iimit of the lacl test in our 
hands lies at a 50-100% increase in mutant fre-
quency. For this comparison we will assume that 
a doubling in mutant frequency can be reliably 
detected in any desired tissue: The rough correla-
tion between lacl results and carcinogenic po-
tency derived from the results in Table 1 showed 
that a doubling in mutant frequency in the lac/ 
system could be obtained if a dose equivalent to 
the TD50 was administered daily for ::::::50 days. 
Furthermore, the data with 2-AAF (Table 1) indi-
cated that the sensitivity of the lacl test could be 
increased by lengthening the treatment period. It 
therefore follows that a detection Iimit equivalent 
to TD 10 might be achieved in the lacl test if 
exposure periods 5 times Ionger were to be used 
(i.e., 250-day exposure at TD 10 Ievel = 50-day ex-
posure at TD50 Ievel = detection Iimit in lacl 
test). 
The following points can be derived from this 
preliminary comparison of detection Iimits. 
(1) The lacl system as a short-term test (acute 
dosing) is less sensitive than classical carcino-
genicity studies. 
(2) A lacl study with a genotoxic chemical given 
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at the maximum tolerated dose for 250 days 
might offer a similar sensitivity as a 2·year 
carcinogenicity study. 
(3) If a positive result is seen in a high·dose 
1-5·day lacl experiment, carcinogenicity in 
rodents could be expected after exposure to 
daily dose Ievels 50-250-fold below the acute 
dose. Such a positive result could be informa-
tive for the prediction of carcinogenic po-
tency. 
(4) A negative result in an acute lac/ test offers 
only a modest margin of safety: a 50-250-fold 
lower daily dose could still produce a measur-
able increase in tumour incidence in a long-
term study. 
(5) The element of exposure period can be used 
advantageously in two ways when designing 
lacl studies. This is illustrated in Fig. 2. Each 
hyperbola represents hypothetical dose-time 
combinations giving the same Iimit of detec-
tion. Firstly, note the dramatic dose reduction 
possible with a relatively small increase in 
treatrnent period as one moves from a 1-day 
to a 4-week exposure period (for example, 
1 X 2.5 gj kg and 25 X 100 mgj kgj day both 
lie on the hyperbola corresponding to a TD 10 
detection Iimit of 10 mgjkgjday). 
Secondly, note how the margin of safety of-
fered by a negative lacl result increases with 
exposure time (Fig. 2, horizontal dotted line): 
the high er the corresponding TD 10, the better 
the detection Iimit and the lower the maxi-
mum possible carcinogenic potency of a test 
chemical. For example, 2 days X 125 mgj kg 
gives a TD 10 detection Iimit of only 1 mgj 
kgj day, whereas 100 days X 125 mgj kg 
would increase the TD 10 detection Iimit to 50 
mgjkgjday. 
Obviously, the above comparison between lacl 
mutant frequency and carcinogenic potency would 
require a much larger data base than presently 
available before risk estimates could be based 
upon it. We are also aware that the factor of 
expression time has not been explicitly incorpo-
rated in this comparison, and that mutagenic-
carcinogenic potency comparisons should be cali-
brated separately for each organ. However, the 
purpose of the above discussion is to encourage a 
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Fig. 2. Daily dose-exposure time combinations in the lacl test 
expected to produce approximately the same Iimit of detec-
tion (TD10) as a 2-year rodent carcinogenicity study with daily 
doses of 1, 10, 50 or 100 mgfkg body weightfday. The values 
along one hyperbola all have the same Iimit of detection. In 
the dashed regions, toxicity might result in deviations from 
these hypothetical curves. The dotted line illustrates the in-
crease in detection limit (and margin of safety) which results 
from dosing at e.g. 125 mgfkg body weightfday for increas-
ingly long time periods. 
quantitative perspective when dealing with lacl 
data and to point out both the possibilities and 
limititations posed by current detection Iimits. 
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